Overview
Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
Indication
For the treatment of epilepsy.
Associated Conditions
No associated conditions information available.
Research Report
Talampanel (DB04982): A Comprehensive Monograph on a Non-Competitive AMPA Receptor Antagonist
Molecular Profile and Physicochemical Properties of Talampanel
Identification and Nomenclature
Talampanel is an investigational small molecule drug that has been the subject of extensive study in neuroscience and oncology. As a synthetic organic compound, its identity is established through a comprehensive set of internationally recognized identifiers, ensuring its unambiguous reference across scientific literature and regulatory databases.
The generic name assigned to the compound is Talampanel, which is also its International Nonproprietary Name (INN), registered under INN number 7820.[1] During its research and development phases, it was known by several codes, most prominently LY300164 and GYKI 53773, reflecting its developmental history with different pharmaceutical entities.[3] Its unique chemical identity is cataloged in major databases under specific accession numbers, including DrugBank ID DB04982, CAS (Chemical Abstracts Service) Registry Number 161832-65-1, and ChEMBL ID CHEMBL61872.[2] Further identifiers such as the FDA UNII code CVS43XG1L5 and PubChem Compound ID 164509 provide additional layers of precise identification for regulatory and research purposes.[3]
Chemical Structure and Stereochemistry
Chemically, Talampanel is classified as a synthetic derivative of dioxolo-benzodiazepine, belonging to the 2,3-benzodiazepine class of compounds known for their activity within the central nervous system (CNS).[3] Its formal IUPAC (International Union of Pure and Applied Chemistry) name is 1-dioxolo[4,5-h]benzodiazepin-7-yl]ethanone.[1]
The structure of Talampanel is defined by several key representations used in computational and medicinal chemistry:
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2009/09/23 | Phase 2 | Terminated | |||
2009/08/25 | Phase 1 | Completed | |||
2009/03/25 | Phase 1 | Terminated | |||
2008/06/12 | Phase 2 | Completed | |||
2005/12/21 | Phase 2 | Completed | |||
2005/04/18 | Phase 2 | Completed | |||
2003/07/09 | Phase 2 | Completed | |||
2003/06/12 | Phase 2 | Terminated | |||
2003/04/02 | Phase 2 | Completed | |||
2002/12/10 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.